How to Appeal a UnitedHealthcare Prior-Authorization Denial for Weight-Loss Medication

By the PriorAuthAppeal editorial team · Sources cited · Independent of UnitedHealthcare

Last reviewed 2026-05-06

UnitedHealthcare covers Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), and Zepbound (tirzepatide) under its Medical Benefit Drug Policy: Weight Loss Pharmacotherapy when patients meet four documented criteria: a qualifying BMI, participation in a lifestyle modification program, absence of specific contraindications, and minimum age requirements. A denial doesn't close the door — UnitedHealthcare allows two internal appeal levels plus an independent external review, and you have up to 180 days from the denial date to file. This guide walks you through exactly what UHC requires, why denials happen, and how to build an appeal strong enough that your physician can send it with confidence.

At a glance

• Covered drugs: Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), Zepbound (tirzepatide)
• BMI threshold: ≥ 30 kg/m² (obesity), OR ≥ 27 kg/m² with at least one weight-related comorbidity
• Recognized comorbidities: Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
• Step-therapy / lifestyle requirement: Documented comprehensive lifestyle modification program (diet + physical activity + behavioral counseling) of at least 6 months — prior to or concurrent with the prescription
• Appeal deadline: 180 days from the date of the denial notice
• Internal appeal levels: 2 (first-level, then second-level/grievance)
• External review: Available after internal appeals are exhausted
• Policy reference: UnitedHealthcare Medical Benefit Drug Policy: Weight Loss Pharmacotherapy (last updated January 2026); searchable at providerportal.uhc.com

How UnitedHealthcare decides whether to cover GLP-1 medications

UnitedHealthcare's approval decision rests on four required criteria that must all be satisfied simultaneously — missing even one typically triggers a denial.

BMI and comorbidity. The foundational threshold is a BMI of 30 kg/m² or higher, which is the clinical definition of obesity. If your BMI falls between 27 and 29.9 — the overweight range — coverage is still possible, but only when you have at least one documented weight-related comorbidity from UHC's recognized list: Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Both thresholds align with the FDA-approved indications for all three covered medications and are supported by the AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (Garvey et al., Endocr Pract. 2023).

Lifestyle modification program. UnitedHealthcare requires documentation of a comprehensive lifestyle modification program covering diet, physical activity, and behavioral components, lasting at least 6 months. This can be satisfied by records from your primary care physician, a registered dietitian, or a formal commercial weight-loss program such as WW or Noom. The program can have run before the prescription was written or can be running concurrently — it doesn't have to be completed first.

Contraindications. The policy excludes patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2) syndrome, and those with a history of severe pancreatitis. These exclusions mirror the FDA-approved labeling for all three drugs.

Age. The standard minimum age is 18. Wegovy carries an additional FDA-approved indication for adolescents aged 12 and older whose BMI is at or above the 95th percentile for their age and sex — UHC's policy reflects that narrower pediatric carve-out.

What makes UnitedHealthcare's policy distinct from other insurers

UHC's GLP-1 coverage policy has at least two features that frequently catch patients off guard, even those who have researched this topic or been covered under a different insurer.

The lifestyle program must be documented, not just described. Many insurers ask your doctor to attest that lifestyle counseling has occurred. UnitedHealthcare goes further by requiring actual documentation — chart notes, program enrollment records, dietitian visit summaries, or similar paper trail. A physician's letter alone stating "the patient has been counseled on diet and exercise" is frequently insufficient and is one of the most common reasons first-level appeals fail at UHC. You need dated records spanning at least 6 months that reference all three components: dietary change, physical activity, and behavioral modification.

The medical benefit placement changes who reviews the claim. Unlike some commercial insurers that process GLP-1 weight-loss drugs entirely as a pharmacy benefit, UnitedHealthcare covers these drugs under its medical benefit, meaning prior-authorization decisions flow through medical management rather than a pharmacy benefit manager. This distinction matters for appeals: you are appealing a medical necessity determination, not a formulary exclusion, which gives you access to the stronger federal protections under ACA Section 2719 and ERISA Section 503 and makes clinical evidence — rather than formulary tier arguments — the most persuasive lever.

Cardiovascular disease stands alone as a comorbidity. Some insurers restrict the "cardiovascular" comorbidity qualifier to specifically defined conditions such as established coronary artery disease or prior myocardial infarction. UHC's policy lists "cardiovascular disease" broadly, which creates an opportunity: conditions such as heart failure, peripheral artery disease, or stroke history may qualify a patient with a BMI between 27 and 29.9, and the ADA Standards of Care 2025, Section 8, explicitly supports GLP-1 agonist use for cardiovascular risk reduction. If you or your doctor hasn't framed an existing cardiovascular diagnosis in the prior-authorization request, that framing gap alone may be fixable on appeal.

The most common reasons UnitedHealthcare denies these requests

Three denial codes appear repeatedly on UHC GLP-1 denials.

• CO-50 (not medically necessary): The most common code. UHC's reviewer concluded that the documentation submitted didn't satisfy the medical necessity criteria — most often because the lifestyle program records were incomplete, or the comorbidity wasn't explicitly tied to the patient's weight in the clinical notes.
• N-130 (consult plan benefits): This code signals that the specific plan the patient is enrolled in excludes weight-loss medications entirely, or that the drug was processed under the wrong benefit. Some employer-sponsored UHC plans have carved out obesity pharmacotherapy. This is a different problem from a medical necessity denial and may require a different strategy (see below).
• N-455 (missing documentation): A procedural denial. Required documentation — most often the 6-month lifestyle program records — was not included in the original prior-authorization submission.

How to address each denial reason

If you received CO-50, the appeal must convert the clinical narrative. Your physician needs to submit a letter that cites your actual BMI (measured, dated), names your qualifying comorbidity with the ICD-10 code, documents the outcome of non-pharmacologic efforts, and explicitly references UHC's own policy criteria. Bolster this with published guidelines: AACE/ACE Garvey et al. 2023 and ADA Standards 2025, Section 8, both recommend pharmacotherapy when lifestyle intervention alone is insufficient. The FDA-approved labeling for Wegovy, Saxenda, and Zepbound all reflect the same BMI thresholds UHC uses — citing label concordance tells the reviewer that approving the request is medically conservative, not experimental.

If you received N-130, first request a full copy of your Summary Plan Description (SPD) and the Evidence of Coverage document. If your employer-sponsored plan explicitly excludes obesity pharmacotherapy, a standard medical necessity appeal won't override a benefits exclusion — but you can ask your HR department whether the plan can be amended, or whether a Section 125 flexible spending arrangement can offset cost. If the denial is really about the drug being processed under the wrong benefit category, your physician's office should resubmit the prior authorization flagged explicitly as a medical benefit request under the Weight Loss Pharmacotherapy policy.

If you received N-455, this is the most straightforward fix. Gather the documentation UHC says is missing — 6 months of dated lifestyle program records — and resubmit the prior authorization before appealing. If you're within the appeal window and your physician believes the original submission was complete, you can simultaneously file a first-level appeal attaching all documentation and arguing the submission was adequate.

Federal and state laws that protect your right to appeal

Federal law creates a floor of rights that applies regardless of which state you live in.

ACA Section 2719 (45 CFR 147.136) applies to most marketplace and fully-insured group health plans. It mandates access to an internal appeal process and, after internal appeals are exhausted, an independent external review by an accredited organization. The external reviewer's decision is binding on UnitedHealthcare. UHC confirms external review is available after both internal levels.

ERISA Section 503 (29 CFR 2560.503-1) governs most employer-sponsored self-funded plans. It requires UHC to provide a written explanation of every denial with specific reasons, identify the clinical criteria applied, and grant you at least 180 days to file an appeal — which matches UHC's stated appeal deadline. If UHC fails to comply with these procedural requirements, the denial itself may be challengeable on procedural grounds.

ACA Section 1557 prohibits discrimination in health programs that receive federal financial assistance. Because obesity is increasingly recognized as a chronic disease — not a lifestyle choice — arguments grounded in Section 1557 have been used to challenge blanket exclusions of obesity treatment. This is a more advanced legal argument, but it is worth raising if your employer's plan excludes obesity drugs while covering analogous treatments for other chronic diseases.

The 180-day appeal deadline is not soft. Mark the date on your denial letter and work backward: gathering records typically takes 10-14 days, physician letter drafting takes another few days. Don't use the full window casually.

What a strong appeal letter contains

A physician-signed appeal letter that succeeds at UnitedHealthcare typically includes each of the following elements.

• Patient demographics and plan/member ID, the specific drug requested, and the denial date and denial code
• Measured BMI with the date of measurement, documented in the medical record
• Named qualifying comorbidity (e.g., "Type 2 diabetes, ICD-10 E11.9") with explicit language connecting the condition to excess weight
• Summary of 6-month lifestyle modification program, with dates, modalities, and the provider or program name — attached as supporting records, not merely described
• Statement that no contraindications are present (no MTC, no MEN-2, no severe pancreatitis history)
• Citation of UHC's own Medical Benefit Drug Policy: Weight Loss Pharmacotherapy, with the specific criteria the patient meets quoted verbatim
• Reference to AACE/ACE Garvey et al. 2023, ADA Standards 2025 Section 8, and the FDA-approved labeling for the specific drug requested
• A specific, affirmative request: "We request reversal of the denial and authorization of [drug name] for [patient name]"

Keep the letter under two pages. Reviewers read many appeals; dense, organized letters with clear headers get read more carefully than long narratives.

Timeline: what happens after you submit your appeal

UnitedHealthcare is required under federal law to decide first-level appeals within specific timeframes from the date the appeal is received.

• Urgent/expedited appeal: Decision within 72 hours — available when your physician certifies that waiting for a standard decision would seriously jeopardize your health
• Standard first-level appeal: Decision within 30 days for pre-service (prior authorization) denials
• Second-level appeal: If you lose the first level, you can file a second-level internal appeal; UHC must again decide within 30 days for pre-service denials
• External review: After both internal levels are exhausted, request independent external review in writing; the external reviewer typically has 45 days to issue a binding decision under 45 CFR 147.136

Track every submission with certified mail or a portal confirmation number. If UHC misses a deadline, that procedural failure strengthens your external review argument.

Frequently asked questions about UnitedHealthcare GLP-1 appeals

Does my 6-month lifestyle program have to be completed before I can start the medication?

No — UnitedHealthcare's policy explicitly permits the lifestyle modification program to run concurrently with pharmacotherapy, not only before it. The key is that you must have at least 6 months of documented participation in a program covering diet, physical activity, and behavioral components. If you've been enrolled in a program like WW or Noom alongside your prescription, those records satisfy the requirement. What the policy doesn't allow is a prior-authorization request with zero lifestyle documentation.

My BMI is 28 — can I still qualify for coverage?

Yes, a BMI between 27 and 29.9 qualifies for coverage under UHC's policy, but only if you have at least one of the five recognized comorbidities: Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The comorbidity must be documented in your medical records and explicitly connected to excess weight. If your physician hasn't made that clinical link in their notes and in the prior-authorization request, that is the gap to fix on appeal.

What if my employer's UHC plan simply excludes weight-loss drugs?

An N-130 denial based on a plan-level exclusion is a benefits dispute, not a medical necessity dispute, and a standard clinical appeal will not override it. Request your Summary Plan Description and confirm whether the exclusion is explicit. If it is, your options include asking your HR department to amend the plan at the next renewal, exploring whether your FSA or HSA can cover medication costs, or asking your physician about alternative diagnoses (such as Type 2 diabetes) under which a GLP-1 drug may be covered as a diabetes treatment rather than a weight-loss treatment — which is a separate coverage category.

Can I go straight to external review without doing both internal appeal levels?

Generally, no. Federal rules under ACA Section 2719 and ERISA Section 503 require you to exhaust UHC's internal appeal process first — meaning both internal levels — before requesting independent external review. The exception is if UHC violates procedural requirements (misses a deadline, fails to provide required information), in which case you may be deemed to have exhausted internal remedies and can proceed directly to external review.

My doctor submitted the prior authorization but didn't include my lifestyle program records. Can I fix that on appeal?

Yes, and this is one of the most fixable denial scenarios. An N-455 denial for missing documentation can be addressed by gathering 6 months of dated lifestyle program records and submitting them with a first-level appeal letter that also reiterates all other qualifying criteria. Be specific: include program enrollment confirmations, visit summaries from a registered dietitian, or chart notes from your primary care physician documenting counseling sessions with dates. The appeal doesn't require you to argue the original submission was correct — it just needs to supply what was missing.

If I lose both internal appeals, what are my chances at external review?

External review success rates vary by case, but external reviewers are independent and not financially tied to UHC's decision. They apply clinical standards, not UHC's internal guidelines, and binding clinical evidence — published guidelines like AACE/ACE Garvey 2023 and ADA 2025 Section 8, plus FDA labeling — carries real weight. The external reviewer's decision is legally binding on UnitedHealthcare, meaning UHC must authorize the drug if the external reviewer rules in your favor.

Get a physician-ready appeal letter in 30 minutes

Building a complete appeal packet — denial letter, clinical records, 6-month lifestyle documentation, and a well-structured physician letter citing UHC's own policy criteria and relevant federal guidelines — takes time that most patients and busy physician offices don't have. If you want a shortcut, PriorAuthAppeal ($59, with a money-back guarantee if your physician declines to sign) generates a customized, physician-ready appeal letter based on your specific denial code, drug, and clinical profile. That said, every tool and citation in this guide is available to you right now, for free. Whether you use a service or build the appeal yourself, the most important thing is to submit before your 180-day deadline and to lead with documentation, not frustration. Insurance reviewers respond to evidence — give them the evidence, and give it to them in the format this guide describes.